Drug intelligence / Profile preview

ART26.12

Development stage: Unknown
Lead developer: Artelo Biosciences
Modality: Small Molecules
Administration: Oral

Overview

ART26.12 is a selective inhibitor of fatty acid-binding protein 5 (FABP5), developed by Artelo Biosciences. It acts by boosting endocannabinoid levels, which has analgesic effects. ART26.12 is being researched as a potential treatment for chemotherapy-induced peripheral neuropathy (CIPN) and other pain conditions, including osteoarthritis. It is a non-opioid, non-steroidal analgesic.

Targets

FABP5 (Fatty acid-binding protein 5)

Beyond the preview

Go deeper on ART26.12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART26.12.

Explore the full profile